Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018 ASD Therapeutics Market Forecast to Show Moderate

Growth until 2018 The Autism Spectrum Disorder (ASD) therapeutics market was valued at $3.1 billion in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.5% over the next eight years to reach $5.5 billion by 2018. This market growth is primarily attributed to the high prevalence (0.6 to 1%) and prevalence growth rate (10-17%) of ASD in the US and in certain European countries. Co-morbidities such as anxiety, epilepsy and depression associated with ASD also contribute to the growth of the ASD therapeutics market. The current competitive landscape consists of two approved drugs, Abilify (aripiprazole) and risperidone, for the treatment of irritability associated with autistic disorder; and psychotropic medications such as anti-psychotics, anti-depressants, anti-convulsants and stimulants which are prescribed off-label. Currently, there is no drug approved to treat the core symptoms of autism such as communication difficulties, social impairment and repetitive and stereotyped patterns of behavior. GlobalDatas research suggests that the ASD pipeline is strong with 23 molecules in various phases of development. Of the 23, there are 12 first-inclass molecules in various phases of development. First-in-class products such as NPL-2008 (novel fast-dissolving low-dose formulation of fluoxetine) and CM-AT (enzyme replacement therapy) are in Phase III of clinical development. The first-inclass molecules are expected to manage the disease better in comparison to the currently prescribed products. GlobalData found that the unmet need of the ASD therapeutics market is high as the treatment relies on off-label psychotropic medications due to the limited numbers of specifically approved therapies available. Therefore, the market requires novel therapies offering better results in terms of safety and efficacy. The first-in-class molecules such as NPL-2008 (novel fast-dissolving low-dose formulation of fluoxetine) and CM-AT (enzyme replacement therapy) are expected to drive the market in future. The existing market landscape remains competitive because the treatment of ASD relies on two approved drugs, Abilify and risperidone; off-label anti-depressants such as olanzapine and fluoxetine and anti-convulsants such as divalproex. The market scenario is expected to change following the launch of innovative and novel therapies. For Sample Pages, please click or add the below link to your browser: http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?ID=Autistic-DisorderTherapeutics-Pipeline-Assessment-and-Market-Forecasts-to2018&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&Comp anyID=fb According to the Centers for Disease Control (CDC), the US, the prevalence of ASD in Europe, North America and Asia was found to be 0.6% to 1%, accounting for approximately six million people in the major markets in 2010. It is expected that the prevalence will grow by approximately 10-17% per year. ASD is normally diagnosed between three to eight years of age. A significant increase in the ASD population has been found in the past decade due to an increase in disease

awareness and diagnosis rate. The above facts demonstrate that the number of ASD patients is expected to grow in the next decade, resulting in an increased usage of drug therapy which in turn will drive the ASD therapeutics market.

For more updates, please join us at facebook: http://www.facebook.com/PharmaceuticalsandHealthcareMarketIntelligence Visit our report store: http://www.globalmarketsdirect.com For more details contact: pressreleases@globalmarketsdirect.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782